银屑病疾病复发的生物学基础:历史视角与当前模型
本综述从历史视角梳理银屑病复发机制,指出皮损消退后局部免疫记忆持续存在,CCR4+表型T细胞亚群形成局部记忆;IL-23/Th17通路在银屑病病理与复发中起关键作用,IL-17和IL-23受体阻滞剂的临床疗效支持这些细胞因子作为治疗靶点。
要点
- 银屑病皮损消退后可见炎症完全消失的皮肤中仍存在局部免疫记忆,导致治疗停止后皮损倾向于在原受累部位复发。
- 消退皮肤中存在大量CD8+和CD4+组织驻留记忆T细胞,可在无血液T细胞募集情况下启动并维持银屑病免疫应答。
- IL-23驱动的产IL-17 T细胞在银屑病病理与复发中起关键作用,使这些细胞因子成为合理的治疗靶点。
核心结论
- 本综述讨论的证据表明,IL-23驱动的产IL-17 T细胞在银屑病病理和复发中起关键作用,使这些细胞因子成为合理的治疗靶点。
研究设计与样本
- 本综述从历史视角梳理银屑病复发生物学基础与当前模型,并解释IL-17和IL-23受体阻滞剂治疗银屑病的临床疗效。
主要发现
- 现有证据支持在可见炎症完全消失后的消退皮肤中存在局部免疫记忆,以及以皮肤趋向性CCR4+表型为特征并形成局部记忆的特定T细胞亚群的作用。
- 对银屑病免疫病理中IL-23/Th17细胞通路认识的增加,正使银屑病不再主要按历史上的Th1型疾病分类。
- 20世纪90年代至2000年代中期开展的研究为消退皮肤中存在大量CD8+和CD4+组织驻留记忆T细胞提供了证据,这些细胞可在无血液T细胞募集情况下启动并维持银屑病免疫应答。
- 树突状细胞(DC)通过分泌IL-23(Th17细胞的上游调节因子)参与银屑病病理,而浆细胞样DC通过IL-36信号和I型干扰素激活参与。
临床怎么用
- 作者认为IL-23驱动的产IL-17 T细胞在银屑病病理和复发中起关键作用,使这些细胞因子成为合理的治疗靶点,并解释了IL-17和IL-23受体阻滞剂治疗银屑病的临床疗效。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
A key challenge in psoriasis therapy is the tendency for lesions to recur in previously affected anatomical locations after treatment discontinuation following lesion resolution. Available evidence supports the concept of a localized immunological 'memory' that persists in resolved skin after complete disappearance of visible inflammation, as well as the role of a specific subpopulation of T cells characterized by the dermotropic CCR4+ phenotype and forming a local memory. Increasing knowledge of the interleukin (IL)-23/T helper 17 (Th17) cell pathway in psoriasis immunopathology is pointing away from the historical classification of psoriasis as primarily a Th1-type disease. Research undertaken from the 1990s to the mid-2000s provided evidence for the existence of a large population of CD8+ and CD4+ tissue-resident memory T cells in resolved skin, which can initiate and perpetuate immune responses of psoriasis in the absence of T-cell recruitment from the blood. Dendritic cells (DCs) are antigen-presenting cells that contribute to psoriasis pathology via the secretion of IL-23, the upstream regulator of Th17 cells, while plasmacytoid DCs are involved via IL-36 signalling and type I interferon activation. Overall, the evidence discussed in this review indicates that IL-23-driven/IL-17-producing T cells play a critical role in psoriasis pathology and recurrence, making these cytokines logical therapeutic targets. The review also explains the clinical efficacy of IL-17 and IL-23 receptor blockers in the treatment of psoriasis.
引用
- Puig L, Costanzo A, Muñoz-Elías EJ, et al. The biological basis of disease recurrence in psoriasis: a historical perspective and current models. Br J Dermatol. 2022. PMID: 34939663. doi:10.1111/bjd.20963
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。